Review Article

Myoferlin, a Membrane Protein with Emerging Oncogenic Roles

Yimin Dong,1 Honglei Kang,1 Huiyong Liu,1 Jia Wang,1 Qian Guo,1 Chao Song,1 Yunlong Sun,1 Ya Zhang,1 Honghua Zhang,1 Zheng Zhang,1 Hanfeng Guan,1 Zhong Fang1,1,2 and Feng Li1,2

1Department of Orthopedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2Biological Engineering and Regenerative Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Correspondence should be addressed to Feng Li; lifengmd@hust.edu.cn

Received 19 June 2019; Revised 2 August 2019; Accepted 21 August 2019; Published 19 November 2019

Academic Editor: Robert J. Lee

Copyright © 2019 Yimin Dong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Myoferlin (MYOF), initially identified in muscle cells, is a member of the Ferlin family involved in membrane fusion, membrane repair, and membrane trafficking. Dysfunction of this protein is associated with muscular dysfunction. Recently, a growing body of studies have identified MYOF as an oncogenic protein. It is overexpressed in a variety of human cancers and promotes tumorigenesis, tumor cell motility, proliferation, migration, epithelial to mesenchymal transition, angiogenesis as well as metastasis. Clinically, MYOF overexpression is associated with poor outcome in various cancers. It can serve as a prognostic marker of human malignant disease. MYOF drives the progression of cancer in various processes, including surface receptor transportation, endocytosis, exocytosis, intercellular communication, fit mitochondrial structure maintenance and cell metabolism. Depletion of MYOF demonstrates significant antitumor effects both in vitro and in vivo, suggesting that targeting MYOF may produce promising clinical benefits in the treatment of malignant disease. In the present article, we reviewed the physiological function of MYOF as well as its role in cancer, thus providing a general understanding for further exploration of this protein.

1. Introduction

MYOF is a member of the Ferlin family that has six Ferlin proteins, Fer-1, Sea urchin Ferlin, Misfire, Otoferlin, MYOF, and dysferlin [1]. Fer-1, Sea urchin Ferlin and Misfire are reported in C. elegans, Sea urchin, Drosophila, respectively. Dysfunction of these proteins is associated with infertility or defective exocytosis [2–4]. Otoferlin, MYOF, and dysferlin are mainly studied in human tissues. Otoferlin exists in the hair cells of the inner ear. Mutation of its gene causes a nonsyndromic prelingual deafness [5]. Dysferlin is highly expressed in human muscular tissues and mediates membrane repair in a Ca2+-dependent manner [6, 7]. Loss of dysferlin is associated with two types of human muscular dystrophy, Miyoshi myopathy and limb girdle muscular dystrophy [8, 9]. Interestingly, MYOF also abounds in human muscular tissue. It is important for membrane repair and myoblast fusion. MYOF-null myoblasts can enter into the initial stage of fusion events, but they lose the ability to form large mature myofibers and to regenerate [10].

MYOF and dysferlin seem to have overlapping roles in skeletal muscles and they may interact with each other [11]. Compared to dysferlin-null mice, mice lacking both myoferlin and dysferlin develop severer muscular damage [12], and transgenic overexpression of MYOF attenuates membrane fusion defects in muscle cells of dysferlin-deficient mice [13]. However, MYOF is mainly located in immature “prefusion” myoblasts, while dysferlin exhibits abundance in mature myotubes [14]. In limb-girdle muscular dystrophy type 2B caused by dysferlin mutation, no difference in muscular MYOF protein level has been observed between mildly and severely affected patients [15]. In dysferlinopathy, compensatory overexpression of myoferlin is absent in affected muscles [16]. These findings indicate that MYOF can partially compensate for the function of dysferlin, but this compensation does not occur naturally as a rescue mechanism in the absence of dysferlin.
While dysferlin is mainly found in muscle tissue, MYOF has been identified in many other tissues and cells, including human airway epithelia [17], human placenta [18, 19], vascular tissues and endothelial cells (ECs) [20]. Recently, increasing studies have revealed that MYOF is overexpressed in many kinds of human cancers, including pancreas cancer [21, 22], ovarian carcinoma [23], prostate cancer [24], breast cancer and renal cell cancer [25, 26], indicating that this protein may have important roles in tumorigenesis and malignant progression. However, the exact role of MYOF in tumorigenesis has not been fully elucidated yet. In the present article, we reviewed the structure and physiological function of MYOF, and summarized the role of MYOF in malignant disease, thus providing a general understanding of this protein.

2. The Structure of MYOF

All six ferlins consist of multiple C2-domains, a centrally-positioned FerA domain and a single C-terminal transmembrane helix. Like other Ferlins, typical structure of MYOF is multiple C2-domains that regulate the protein's function by forming Ca\(^{2+}\)-dependent phospholipid complex [27]. MYOF has seven C2-domains (Figure 1). These C2-domains can bind to lipid layers and change the structure of lipid packing, forming regional distorted membrane structure responsible for fusion and fission events [28]. C2-domains are surrounded by a ring of positive charges. Ca\(^{2+}\)-binding to C2-domains causes a major change in the electrostatic potential and mediates binding with target molecules [29]. C2-domains of MYOF have equivalent Ca\(^{2+}\)-binding affinity, which is weaker than that of Dysferlin, however [30]. FerA domain is a four-Helix bundle domain associated with the membrane. MYOF FerA domain preferably binds to negatively-charged phospholipids. This domain has no Ca\(^{2+}\)-binding site, but its binding activity can be enhanced by Ca\(^{2+}\) [31]. MYOF and dysferlin have additional DysF domain other than Ferlin proteins (Figure 1). DysF domain of MYOF can bind to caveolin-3, a protein that functions as a component of the caveolae plasma membrane found in most cell types [32].

3. MYOF Is Involved in a Wide Range of Membrane Trafficking Events

MYOF is expressed in various membrane structures, including the plasma membrane, perinuclear vesicular puncta, Rab7-positive endosomes as well as cell periphery [33], indicating that it participates in a wide range of membrane trafficking processes (Figure 2). Doherty et al. have reported that MYOF participates in endocytic trafficking by interacting with EH domain containing protein 2 (EHD2) [34]. EHD proteins, including EHD1-4, are associated with endocytic transport such as cell surface receptor internalization and recycling [35, 36]. MYOF depletion decreases EHD2 level and delays recycling of foreign protein such as transferrin, resulting in delayed recycling and intracellular accumulation of transferrin after its internalization [34]. In myoblasts, EHD1 is co-localized with MYOF, forming a pre-fusion complex that is directed to surface membrane by the Rho-GAP, GRAF1 (GTPase regulator associated with focal adhesion kinase-1). Knockdown of any of these three proteins can impair myoblast fusion, suggesting a multiple, not single protein involvement in MYOF-mediated membrane fusion events [37, 38].

MYOF also participates in recycling of insulin-like growth factor (IGF) receptor (Figure 2), which initiates an important signaling for normal myogenesis. MYOF depletion stalls IGF receptor recycling to the plasma membrane and redirects it toward lysosomal degradation, resulting in hampered IGF receptor related pathway as well as unresponsiveness to IGF1 stimulation both in vitro and in vivo [39]. In endothelial cells (ECs), MYOF forms a complex with vascular endothelial growth factor receptor 2 (VEGFR-2) and mediates its membrane-oriented expression [20]. MYOF prevents VEGFR-2 from polyubiquitination as well as proteasomal degradation (Figure 2). Loss of MYOF reduces VEGF-mediated activation of key intracellular signaling cascades, such as ERK-1/2, JNK, and PLCγ. Another EC-specific angiogenic receptor of angiopoietin-1, Tie-2, also necessities MYOF for normal membrane localization [40]. MYOF silencing exhibits significant antiangiogenic effects, indicating that it is a potential antiangiogenic target and targeting this protein may yield potential therapeutic benefits in angiogenesis-related disease.

Another study has revealed that MYOF participates in caveolae/lipid raft and clathrin-mediated endocytosis by forming a complex with dynamin-2 (Dyn-2) and caveolin-1 (Cav-1) [41]. Dyn-2 is essential for the fission process of endocytic vesicle, while Cav-1 is a structural component of caveolae. The MYOF/Dyn-2/Cav-1 complex is required for endocytosis and membrane repair. Respective loss of the three proteins impairs endocytosis of transferrin and leads to equal loss of membrane resealing following membrane injury [41, 42]. In addition to endocytosis, a recently published study has uncovered the role of MYOF in lysosomal exocytosis of phagocytes [43]. MYOF mediates fusion of exocytotic lysosome to the membrane and helps to release lysosome contents, including hydrolytic enzymes, which increase cytotoxicity (Figure 2). It is possible that MYOF is involved in phagocyte-mediated inflammation and antitumor effects by enhancing its cytotoxicity effects.
Schiller et al. have reported that MYOF is also present at extracellular membrane structures [44] and interacts with leukocyte specific transcript 1 (LST1), a transmembrane MHC class III protein that can induce the formation of tunneling nanotubes (TNT) essential for cell-to-cell communication [45]. MYOF is speculated to drive LST1-induced TNT formation by locally deforming the plasma membrane and mediating membrane fusion [44]. Blomme et al. have identified the expression of MYOF in tumor cell derived exosomes. MYOF depletion decreases the ability of such exosomes to induce migration and proliferation of human endothelial cells [46]. However, further studies are required to elucidate the exact role of MYOF in extracellular structures in different cells and tissues and to explore its association with human disease.

4. Role of MYOF in Cancer

As reviewed above, MYOF is implicated in a wide range of membrane-associated events. It is likely that cancer cells also replicate the role of MYOF to facilitate their progression because they are highly active in membrane-associated events to maintain a malignant phenotype. Recently, emerging studies have revealed that MYOF is overexpressed in many cancers. Overexpression of MYOF is associated with poor prognosis in patients with breast cancer, lung cancer, and pancreas cancer [47, 48]. In pancreas adenocarcinoma (PAC), MYOF expression is negatively correlated with the degree of histological differentiation and patients with MYOF-overexpressing MYOF have poor total survival rate after surgical treatment. In addition, MYOF has been found to have recurrent mutations which are associated with the clinical outcome of patients with non-small cell lung cancer [49]. In oropharyngeal squamous cell carcinoma (OPSCC), nuclear location of MYOF is significantly related to poor prognosis, as patients with nuclear MYOF+/IL-6+OPSCC have the worst, whereas nuclear MYOF−/IL-6−OPSCC have the best outcome [50]. However, this is not the same case in all cancers. In endometrioid carcinoma, moderate to strong expression of MYOF is observed in normal epithelial tissue and low-grade carcinoma tissue, whereas weak to negative expression is found in high-grade carcinoma tissue [51]. MYOF contributes to tumorigenesis in various processes, and the mechanisms are discussed as follows based on available data.

4.1. MYOF in Breast Cancer. MYOF has been intensively studied in breast cancer, which is one of the most common cancers worldwide and represents the leading cause of cancer related female death [52]. In human breast cancer cells, MYOF regulates cell-matrix adhesion by affecting the strength of focal adhesion, structure that plays a crucial role in cell migration...
potent antitumor effects similar to that of MYOF depletion [64]. Such MYOF-targeting compounds are expected to yield promising therapeutic benefits in the treatment of cancer.

Blomme et al. have described that MYOF is involved in lipid trafficking and mitochondrial function [65]. Intracellular transportation of lipids is blocked in cells deficient in MYOF, leading to increased accumulation of lipids and fatty acids, which impairs mitochondrial function and results in marked alteration of cell metabolism [65]. It is widely acknowledged that tumor cells tend to favor metabolism via glycolysis rather than oxidative phosphorylation, which is termed as the Warburg effect [66]. However, accumulating evidence has revealed that they also tend to produce energy through oxidative phosphorylation to sustain survival and metastasis [67]. MYOF depletion decreases the oxidative phosphorylation (OXPHOS) as well as ATP production and redirects tumor cells toward glycolysis. However, this metabolic change renders tumor cells more susceptible to metabolism-targeting drugs, which might be a potential combined therapy for the prevention of tumor invasion [65].

4.2. MYOF in Digestive Organ Cancers. MYOF has also been explored in cancers of digestive organs, including pancreas, liver and colon. High expression of MYOF is associated with high density of blood vessels in pancreas cancer [68]. MYOF can facilitate secretion of vascular endothelial growth factor A (VEGFA) (Figure 2), a key factor for angiogenesis, while MYOF silencing impairs exocytosis of VEGFA by blocking the fusion process of VEGFA-containing vesicles with plasma membrane, which reduces VEGFA secretion from tumor cells and in return attenuates tumor-related angiogenesis.
Both MLK 1/2 and SRF are onco-
genic drivers for hepatocellular cancer [75, 76]. MLK1/2 and
SRF can bind to the promoter of MYOF gene and activate its
expression. Either MKL1/2 or SRF depletion decreases
MYOF level and triggers EGFR phosphorylation similar to
that in breast cancer cells [56]. In HCCs, phosphorylated
EGFR activates its downstream Ras/MEK/ERK cascade and
induced oncogene-induced senescence (OIS) (Figure 3). As
senescence induction is an emerging strategy for the treat-
ment of HCC, it is possible that intervening in the MKL1/2—
SRF-MYOF signaling pathway may contribute to the
treatment of hepatocellular cancer [74].

4.3. Role of MYOF in Other Cancers. As an on
cogenic protein, MYOF is ubiquitously expressed in human epithelial
cancers. Study by Leung et al. has revealed that MYOF is
overexpressed in Mouse Lewis lung carcinoma (LLC) cell. It
is essential for plasma membrane integrity and LCC tumor
cell proliferation [77]. In melanoma, MYOF contributes to the formation
of Vasculogenic mimicry (VM), an important mechanism
to facilitate tumor metastasis. MYOF depletion decreases
exocytosis of MMP2 and VM formation, which further
attenuates migration and invasion [78]. In the molecule level,
MYOF serves as a chaperone protein in IL6/STAT3 signaling
cascade and its activity is naturally suppressed by EHD2
in resting cells [79]. Upon the stimulation of IL-6, IL-6R
activates STAT3 phosphorylation and MYOF dissociation from
EHD2. Then, phosphorylated STAT3 translocates to nucleus

cancer cells (HCCs) [74]. Both MLK 1/2 and SRF are onco-
genic drivers for hepatocellular cancer [75, 76]. MLK1/2 and
SRF can bind to the promoter of MYOF gene and activate its
expression. Either MKL1/2 or SRF depletion decreases
MYOF level and triggers EGFR phosphorylation similar to
that in breast cancer cells [56]. In HCCs, phosphorylated
EGFR activates its downstream Ras/MEK/ERK cascade and
induced oncogene-induced senescence (OIS) (Figure 3). As
senescence induction is an emerging strategy for the treat-
ment of HCC, it is possible that intervening in the MKL1/2—
SRF-MYOF signaling pathway may contribute to the
treatment of hepatocellular cancer [74].

In colon cancer, MYOF silencing leads to accumulation of
reactive oxygen species (ROS) and DNA damage. Increased
ROS triggers p53 activation [71], which then provokes cell
cycle arrest and results in p53-dependent reduction of cell
growth. Reactivation of p53 can enhance the inhibition effects
of MYOF-silencing on tumor cell growth, indicating that
MYOF drives oncogenesis in colon cancer possibly by inhib-
iting the function of p53 [72]. It is anticipated that combina-
tion of MYOF-targeting and p53 modulation might yield new
perspectives in the treatment of colon cancer.

Most studies on MYOF in human cancer are mainly cen-
tred on its oncogenic functions, but little has been known
about how MYOF gene expression is regulated. Previous
study has shown that nuclear factor of activated T cells
(NFAT) can bind to the promoter of MYOF gene and upreg-
ulate MYOF expression in fusing myoblasts and damaged
MYOF fibers [73], but little is known about how MYOF gene
expression is regulated in cancer cells. Hermann et al. have
identified MYOF as a target gene downstream of the MLK1/2-
SRF signaling axis in human and marine hepatocellular

![Figure 4: The role of MYOF in IL-6R related pathway. Activity of MYOF is inhibited by EDH2 on cell membrane. Upon stimulation
by IL-6, IL-6R phosphorylates STAT3, which interacts with MYOF and translocates to the nucleus. Phosphorylated STAT3 activates
its target gene expression and promotes tumor progression.](image-url)
chaperoned by MYOF and activates downstream genes of the IL6/STAT3 pathway, thus potentiating tumor cell motility and cancer stem cell phenotype (Figure 4). In follicular lymphoma, MYOF has been identified as a self-antigen that can be recognized by surface BCR of malignant B-cell clone from a patient with follicular lymphoma. This self-antigenic recognition activates BCR-mediated signaling and provides survival signals to tumor cells [80].

5. Conclusion

Although initially discovered in skeletal muscle, MYOF has been found to abound in many other tissues as well as various cancers. This membrane protein mediates receptor internalization and recycling, endocytosis, exocytosis, and intercellular membrane structures. It is also associated with poor prognosis in many malignant diseases clinically. MYOF serves as an oncogenic protein implicated in various processes of tumor progression, including tumor cell proliferation, migration, invasion, EMT, angiogenesis, and metastasis (Table 1). Targeting MYOF with small interfering RNA and chemical molecules such as WJ460 has demonstrated significant anti-tumor effects in cancer, indicating that MYOF may be a potential target in the treatment of human cancer. We believe more compounds interfering with MYOF will be discovered, and further studies might be centred on the clinical use of such MYOF-targeting compounds.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Yimin Dong and Feng Li searched literatures, collected data, and prepared the initial manuscript. All coauthors took part in revision of the review.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 81874024).

References

[1] A. Lek, F. J. Evesson, R. B. Sutton, K. N. North, and S. T. Cooper, "Ferlins: regulators of vesicle fusion for auditory neurotransmission, receptor trafficking and membrane repair," Traffic, vol. 13, no. 2, pp. 185–194, 2012.
[2] N. L. Washington, "FER-1 regulates Ca2+-mediated membrane fusion during C. elegans spermatogenesis," Journal of Cell Science, vol. 119, no. 12, pp. 2552–2562, 2006.
[3] J. F. Covian-Naures, S. V. Koushik, R. H. L. Puhl, and S. S. Vogel, "Membrane wounding triggers ATP release and dysferlin-mediated intercellular calcium signaling," Journal of Cell Science, vol. 123, no. 11, pp. 1884–1893, 2010.
[4] M. K. Smith and B. T. Wakimoto, "Complex regulation and multiple developmental functions of misfire, the Drosophila melanogaster ferlin gene," BMC Developmental Biology, vol. 7, no. 1, p. 21, 2007.
[5] S. Yasunaga, M. Grati, M. Cohen-Salmon et al., "A mutation in OTOF, encoding otoferlin, a FER-1-like protein, causes DFNB9, a nonsyndromic form of deafness," Nature Genetics, vol. 21, no. 4, pp. 363–369, 1999.

Table 1: Role of MYOF in specific tumor and its clinical significance.

| Cancer type                  | Expression | Tumor biology                                      | Clinical significance                        | Reference |
|------------------------------|-----------|----------------------------------------------------|---------------------------------------------|-----------|
| Breast cancer                | Increased | Increased cell proliferation, migration, invasion, EMT and metastasis | Poor outcome                               | [55, 56, 60, 65] |
| Pancreas cancer              | Increased | Increased cell proliferation, migration and mitochondrial fitness | Poor prognosis and decreased overall survival | [48, 68, 70] |
| Lung cancer                  | Increased | Increased proliferation and angiogenesis            | Poorer prognosis                            | [47, 77]  |
| Liver cancer                 | Increased | Increased cell growth, invasion and proliferation   | Not reported                                | [74]      |
| Melanoma                     | Increased | Increased EMT, migration and invasion              | Poor prognosis                              | [78]      |
| Head and neck squamous cell carcinoma | Increased | Increased migration, metastasis                    | Poor overall survival, tumor recurrence, perineural invasion and distal metastasis | [50, 79] |
| Follicular lymphoma          | Increased | Self-antigenic recognition, BCR-mediated signaling | The patient died                            | [80]      |
| Endometrioid carcinoma       | Decreased | No data                                            | FIGO histologic grading score                | [51]      |
| Colon cancer                 | Increased | Mitochondrial fitness                              | Low patient survival                        | [72]      |
| Renal cancer                 | Increased | No data                                            | Predication of subsequent primary malignancy | [26, 81] |

chaperoned by MYOF and activates downstream genes of the IL6/STAT3 pathway, thus potentiating tumor cell motility and cancer stem cell phenotype (Figure 4). In follicular lymphoma, MYOF has been identified as a self-antigen that can be recognized by surface BCR of malignant B-cell clone from a patient with follicular lymphoma. This self-antigenic recognition activates BCR-mediated signaling and provides survival signals to tumor cells [80].

5. Conclusion

Although initially discovered in skeletal muscle, MYOF has been found to abound in many other tissues as well as various cancers. This membrane protein mediates receptor internalization and recycling, endocytosis, exocytosis, and intercellular membrane structures. It is also associated with poor prognosis in many malignant diseases clinically. MYOF serves as an oncogenic protein implicated in various processes of tumor progression, including tumor cell proliferation, migration, invasion, EMT, angiogenesis, and metastasis (Table 1). Targeting MYOF with small interfering RNA and chemical molecules such as WJ460 has demonstrated significant anti-tumor effects in cancer, indicating that MYOF may be a potential target in the treatment of human cancer. We believe more compounds interfering with MYOF will be discovered, and further studies might be centred on the clinical use of such MYOF-targeting compounds.

Conflicts of Interest

The authors declare that they have no conflicts of interest.
the human placenta, only Dysferlin expression is responsive to
Vandre, “While Dysferlin and Myoferlin are coexpressed in
adeno-carcinoma using cDNA microarrays,” /T_he American
Exploration of global gene expression patterns in pancreatic
adenocarcinoma using cDNA microarrays,” The American
Journal of Pathology, vol. 162, no. 4, pp. 1151–1162, 2003.

[6] D. Bansal, K. Miyake, S. S. Vogel et al., “Defective membrane
repair in dysferlin-deficient muscular dystrophy,” Nature, vol.
423, no. 6936, pp. 168–172, 2003.

[7] D. B. Davis, A. J. Delmonte, C. T. Ly, and E. M. McNally,
“Myoferlin, a candidate gene and potential modifier of muscular
dystrophy,” Human Molecular Genetics, vol. 9, no. 2, pp. 217–
226, 2000.

[8] M. Fardeau, R. H. Brown, P. J. de Jong et al., “Dysferlin, a novel
skeletal muscle gene, is mutated in Miyoshi myopathy and limb
girdle muscular dystrophy,” Nature Genet, vol. 20, no. 1, pp.
31–36, 1998.

[9] L. V. Anderson, K. Davison, J. A. Moss et al., “Dysferlin is a
plasma membrane protein and is expressed early in human
development,” Human Molecular Genetics, vol. 8, no. 5, pp.
855–861, 1999.

[10] K. R. Doherty, A. Cave, D. B. Davis et al., “Normal myoblast
fusion requires myoferlin,” Development, vol. 132, no. 24, pp.
5565–5575, 2005.

[11] A. de Morré, P. J. Hensbergen, H. H. H. B. M. van Haagen et al.,
“Proteomic analysis of the Dysferlin protein complex unveils its
importance for sarcocellular maintenance and integrity,” PloS
One, vol. 5, no. 11, p. e13854, 2010.

[12] A. R. Demonbreun, A. E. Rossi, M. G. Alvarez et al., “Dysferlin
and Myoferlin regulate transverse tubule formation and glycerol
sensitivity,” The American Journal of Pathology, vol. 184, no. 1,
pp. 248–259, 2014.

[13] W. Lostal, M. Bartoli, C. Roudaut et al., “Lack of correlation
between outcomes of membrane repair assay and correction of
dystrophic changes in experimental therapeutic strategy in
dysferlinopathy,” PloS One, vol. 7, no. 5, p. e38036, 2012.

[14] D. B. Davis, K. R. Doherty, A. J. Delmonte, and E. M. McNally,
“Calcium-sensitive phospholipid binding properties of normal
and mutant ferlin C2 domains,” Journal of Biological Chemistry,
vol. 277, no. 25, pp. 22883–22888, 2002.

[15] M. Vainzof, L. V. B. Anderson, E. M. McNally et al., “Dysferlin
protein analysis in limb-girdle muscular dystrophies,” Journal of
Molecular Neuroscience, vol. 17, no. 1, pp. 71–80, 2001.

[16] M. Inoue, Y. Wakyama, H. Kojiima et al., “Expression of
Myoferlin in skeletal muscles of patients with dysferlinopathy,”
The Tohoku Journal of Experimental Medicine, vol. 209, no. 2,
pp. 109–116, 2006.

[17] C. Leung, F. Shaheen, P. Bernatchez, and T.-L. Hackett,
“Expression of myoferlin in human airway epithelium and its
role in cell adhesion and zonula occludens-1 expression,” PloS
One, vol. 7, no. 7, p. e40478, 2012.

[18] J. M. Robinson, D. D. Vandré, and W. E. Ackerman,
“Placental proteomics: a shortcut to biological insight,” Placenta,
vol. 30, pp. 83–89, 2009.

[19] J. M. Robinson, W. E. Ackerman, N. J. Behrendt, and D. D.
Vandre, “While Dysferlin and Myoferlin are coexpressed in
the human placenta, only Dysferlin expression is responsive to
trophoblast fusion in model systems I,” Biology of Reproduction,
vol. 81, no. 1, pp. 33–39, 2009.

[20] P. N. Bernatchez, L. Accevedo, C. Fernandez-Hernando et al.,
“Myoferlin regulates vascular endothelial growth factor
receptor-2 stability and function,” Journal of Biological
Chemistry, vol. 282, no. 42, pp. 30745–30753, 2007.

[21] C. A. Iacobuzio-Donahue, A. Maitra, M. Olsen et al., “Exploration of
global gene expression patterns in pancreatic adenocarcinoma using
cDNA microarrays,” The American Journal of Pathology, vol. 162, no.
4, pp. 1151–1162, 2003.

[22] A. Turtoi, D. Musmeci, Y. Wang et al., “Identification of novel
accessible proteins bearing diagnostic and therapeutic potential
in human pancreatic ductal adenocarcinoma,” Journal of
Proteome Research, vol. 10, no. 9, pp. 4302–4313, 2011.

[23] A. P. N. Skubitz, S. E. Pambuccian, P. A. Argenta, and K. M.
Skubitz, “Differential gene expression identifies subgroups of
ovarian carcinoma,” Translational Research, vol. 148, no. 5, pp.
223–248, 2006.

[24] G. Kristiansen, C. Pilarsky, C. Wissmann et al., “Expression
profiling of microdissected matched prostate cancer samples
reveals CD166/MEMD and CD24 as new prognostic markers
for patient survival,” The Journal of Pathology, vol. 205, no. 3,
pp. 359–376, 2005.

[25] S. Amatschek, U. Koening, H. Auer et al., “Tissue-wide expression
profiling using cDNA subtraction and microarrays to identify
tumor-specific genes,” Cancer Research, vol. 64, no. 3, pp.
844–856, 2004.

[26] D. H. Song, G. H. Ko, J. H. Lee et al., “Prognostic role of
myoferlin expression in patients with clear cell renal cell
carcinoma,” Oncotarget, vol. 8, no. 51, p. 89033, 2017.

[27] O.-H. Shin, W. Han, Y. Wang, and T. C. Südhof, “Evolutionarily
conserved multiple C2 domain proteins with two transmembrane
regions (MCTPs) and unusual Ca2+ binding properties,” Journal of
Biological Chemistry, vol. 280, no. 2, pp. 1641–1651, 2005.

[28] N. J. Marty, C. L. Holman, N. Abdullah, and C. P. Johnson,
“The C2 domains of Otoferlin, Dysferlin, and Myoferlin alter
the packing of lipid bilayers,” Biochemistry, vol. 52, no. 33,
pp. 5585–5592, 2013.

[29] T. C. Südhof and J. Rizo, “Synaptotagmins: C2-domain proteins
that regulate membrane traffic,” Neuron, vol. 17, no. 3, pp.
379–388, 1996.

[30] F. M. Harsini, A. A. Bui, A. M. Rice et al., “Structural basis
for the distinct membrane binding activity of the homologous
C2A domains of Myoferlin and Dysferlin,” Journal of Molecular
Biology, vol. 431, no. 11, pp. 2112–2126, 2019.

[31] F. M. Harsini, S. Chebrolu, K. L. Fuson, M. A. White, A. M.
Rice, and R. B. Sutton, “FerA is a membrane-associating four-
helix bundle domain in the ferlin family of membrane-fusion
proteins,” Scientific Reports, vol. 8, no. 1, 2018.

[32] P. Patel, R. Harris, S. M. Geddes et al., “Solution structure of
the inner DysF domain of Myoferlin and implications for
limb girdle muscular dystrophy type 2B,” Journal of Molecular
Biology, vol. 379, no. 5, pp. 981–990, 2008.

[33] M. G. I. Redpath, R. A. Sophocleous, L. Turnbull, C. B.
Whitchurch, and S. T. Cooper, “Ferlins show tissue-specific
expression and segregate as plasma membrane/late endosomal
or trans-golgi/recycling ferlins,” Traffic, vol. 17, no. 3, pp.
245–266, 2016.

[34] K. R. Doherty, A. R. Demonbreun, G. Q. Wallace et al., “The
endocytic recycling protein EHD2 interacts with Myoferlin to
regulate myoblast fusion,” Journal of Biological Chemistry,
vol. 283, no. 29, pp. 20252–20260, 2008.

[35] N. Naslavsky and S. Caplan, “EHD proteins: key conductors of
endocytic transport,” Trends in Cell Biology, vol. 21, no. 2,
pp. 122–131, 2011.

[36] D. Rapaport, W. Auerbach, N. Naslavsky et al., “Recycling to
the plasma membrane is delayed in EHD1 knockout mice,” Traffic,
vol. 7, no. 1, pp. 52–160, 2006.

[37] K. C. Lenhart, A. L. Becherer, J. Li et al., “GRAF1 promotes
ferlin-dependent myoblast fusion,” Developmental Biology,
vol. 393, no. 2, pp. 298–311, 2014.
[38] J. A. D. Posey, P. Pytel, K. Gardikiotes et al., “Endocytic recycling proteins EHD1 and EHD2 interact with fer-1-like-5 (Fer1L5) and mediate myoblast fusion,” *The Journal of Biological Chemistry*, vol. 286, no. 9, pp. 7379–7388, 2011.

[39] A. R. Demonbreun, A. D. Posey, K. Heretis et al., “Myoferlin is required for insulin-like growth factor response and muscle growth,” *FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology*, vol. 24, no. 4, p. 1284, 2010.

[40] C. Yu, A. Sharma, A. Trane, S. Utokaparch, C. Leung, and P. Bernatchez, “Myoferlin gene silencing decreases Tie-2 expression in vitro and angiogenesis in vivo,” *Vascular Pharmacology*, vol. 55, no. 1–3, pp. 26–33, 2011.

[41] P. N. Bernatchez, A. Sharma, P. Kodaman, and W. C. Sessa, “Myoferlin is critical for endocytosis in endothelial cells,” *American Journal of Physiology-Cell Physiology*, vol. 297, no. 3, pp. C484–C492, 2009.

[42] S. Cipta and H. H. Patel, “Molecular bandages: inside-out, outside-in repair of cellular membranes. Focus on ‘Myoferlin is critical for endocytosis in endothelial cells,’” *American Journal of Physiology-Cell Physiology*, vol. 297, no. 3, pp. C481–C483, 2009.

[43] Y. Miyatake, T. Yamano, and R. Hanayama, “Myoferlin-mediated lysosomal exocytosis regulates cytotoxicity by phagocytes,” *The Journal of Immunology*, vol. 201, no. 10, pp. 3051–3057, 2018.

[44] C. Schiller, K. N. Diakopoulos, I. Rohwedder et al., “LST1 promotes the assembly of a molecular machinery responsible for tunneling nanotube formation,” *Journal of Cell Science*, vol. 126, no. 3, pp. 767–777, 2013.

[45] A. Chauveau, A. Acher, P. Eissmann, E. Vivier, and D. M. Davis, “Membrane nanotubes facilitate long-distance interactions between natural killer cells and target cells,” *Proceedings of the National Academy of Sciences*, vol. 107, no. 12, pp. 5545–5550, 2010.

[46] A. Blomme, K. Fahmy, O. Peulen et al., “Myoferlin is a novel exosomal protein and functional regulator of cancer-derived exosomes,” *Oncotarget*, vol. 7, no. 50, pp. 83669–83683, 2016.

[47] D. H. Song, G. H. Ko, J. H. Lee et al., “Myoferlin expression in non-small cell lung cancer: Prognostic role and correlation with VEGFR-2 expression,” *Oncology Letters*, vol. 11, no. 2, pp. 998–1006, 2016.

[48] W.-S. Wang, X.-H. Liu, L.-X. Liu et al., “iTRAQ-based quantitative proteomics reveals myoferlin as a novel prognostic predictor in pancreatic adenocarcinoma,” *Journal of Proteomics*, vol. 91, pp. 453–465, 2013.

[49] Z. Sun, L. Wang, B. W. Eckloff et al., “Conserved recurrent gene mutations correlate with pathway deregulation and clinical outcomes of lung adenocarcinoma in never-smokers,” *BMC Medical Genomics*, vol. 7, no. 1, p. 32, 2014.

[50] B. Kumar, N. V. Brown, B. J. Swanson et al., “High expression of myoferlin is associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with HPV-status,” *Oncotarget*, vol. 7, no. 14, pp. 18665–18677, 2016.

[51] M. H. Kim, D. H. Song, G. H. Ko et al., “Myoferlin expression and its correlation with FIGO histologic grading in early-stage endometrioid carcinoma,” *Journal of Pathology and Translational Medicine*, vol. 52, no. 2, pp. 93–97, 2018.

[52] E. Bray, J. Ferlay, I. Soerjomataram, L. A. Siegel, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” *CA: A Cancer Journal for Clinicians*, vol. 68, no. 6, pp. 394–424, 2018.

[53] D. J. Webb, K. Donais, L. A. Whitmore et al., “FAK-CSrc signalling through pxaxillin, ERK and MLCK regulates adhesion disassembly,” *Nature Cell Biology*, vol. 6, no. 2, pp. 154–161, 2004.

[54] Y. Wang and M. A. McNiven, “Invasive matrix degradation at focal adhesions occurs via protease recruitment by a FAK-Cp130CAS complex,” *The Journal of Cell Biology*, vol. 196, no. 3, pp. 375–385, 2012.

[55] B. N. Blackstone, R. Li, W. E. Ackerman, S. N. Ghadiali, H. M. Powell, and D. A. Kniss, “Myoferlin depletion elevates focal adhesion kinase and pxaxillin phosphorylation and enhances cell-matrix adhesion in breast cancer cells,” *American Journal of Physiology-Cell Physiology*, vol. 308, no. 8, pp. C642–C649, 2015.

[56] A. Turtoi, A. Blomme, A. Bellahcene et al., “Myoferlin is a key regulator of EGFR activity in breast cancer,” *Cancer Research*, vol. 73, no. 17, pp. 5438–5448, 2013.

[57] J. S. Rush, L. M. Quinlal, L. Engelman, D. M. Sherry, and B. P. Ceresa, “Endosomal accumulation of the activated epidermal growth factor receptor (EGFR) induces apoptosis,” *Journal of Biological Chemistry*, vol. 287, no. 1, pp. 712–722, 2011.

[58] L. I. Volakis, R. Li, T. W. E. Ackerman et al., “Loss of myoferlin redirects breast cancer cell motility towards collective migration,” *PloS One*, vol. 9, no. 2, p. e86110, 2014.

[59] R. Li, T. W. E. Ackerman, C. Mihai, L. I. Volakis, S. Ghadiali, and D. A. Kniss, “Myoferlin depletion in breast cancer cells promotes mesenchymal to epithelial shape change and stalls invasion,” *PloS One*, vol. 7, no. 1, p. e39766, 2012.

[60] M. C. Eisenberg, Y. Kim, R. Li, W. E. Ackerman, D. A. Kniss, and A. Friedman, “Mechanistic modeling of the effects of myoferlin on tumor cell invasion,” *Proceedings of the National Academy of Sciences*, vol. 108, no. 50, pp. 20078–20083, 2011.

[61] S. Lamouille, J. Xu, and R. Derynck, “Molecular mechanisms of epithelial ‘Mesenchymal transition,’” *Nature Reviews Molecular Cell Biology*, vol. 15, no. 3, pp. 178–196, 2014.

[62] Y. Zhou, L. Xiong, Y. Zhang, R. Yu, X. Jiang, and G. Xu, “Quantitative proteomics identifies myoferlin as a novel regulator of A Disintegrin and Metalloproteinase 12 in Hela cells,” *Journal of Proteomics*, vol. 148, pp. 94–104, 2016.

[63] T. Zhang, J. Li, Y. He et al., “A small molecule targeting myoferlin exerts promising anti-tumor effects on breast cancer,” *Nature Communications*, vol. 9, no. 1, 2018.

[64] Y. Li, Y. He, T. Shao et al., “Modification and biological evaluation of a series of 1,5-Diaryl-1,2,4-triazole compounds as novel agents against pancreatic cancer metastasis through targeting myoferlin,” *Journal of Medicinal Chemistry*, vol. 62, no. 10, pp. 4949–4966, 2019.

[65] A. Blomme, B. Costanza, P. de Tullio et al., “Myoferlin regulates cellular lipid metabolism and promotes metastases in triple-negative breast cancer,” *Oncogene*, vol. 36, no. 15, pp. 2116–2130, 2017.

[66] N. N. Pavlova and C. B. Thompson, “The emerging hallmarks of cancer metabolism,” *Cell Metabolism*, vol. 23, no. 1, pp. 27–47, 2016.

[67] V. S. LeBlue, J. T. O Connell, K. N. Gonzalez Herrera et al., “PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis,” *Nature Cell Biology*, vol. 16, no. 10, pp. 992–1003, 2014.

[68] K. Fahmy, A. Gonzalez, M. Arafa et al., “Myoferlin plays a key role in VEGFA secretion and impacts tumor-associated angiogenesis in human pancreas cancer,” *International Journal of Cancer*, vol. 138, no. 3, pp. 652–663, 2016.
[69] G. Rademaker, B. Costanza, S. Anania et al., "Myoferlin contributes to the metastatic phenotype of pancreatic cancer cells by enhancing their migratory capacity through the control of oxidative phosphorylation," Cancers (Basel), vol. 11, no. 6, p. 853, 2019.

[70] G. Rademaker, V. Hennequiere, L. Brohee et al., "Myoferlin controls mitochondrial structure and activity in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness," Oncogene, vol. 37, no. 32, pp. 4398–4412, 2018.

[71] V. J. N. Bykov, J. M. R. Lambert, P. Hainaut, and K. G. Wiman, "Mutant p53 rescue and modulation of p53 redox state," Cell Cycle, vol. 8, no. 16, pp. 2509–2517, 2009.

[72] G. Rademaker, B. Costanza, J. Bellier et al., "Human colon cancer cells highly express myoferlin to maintain a fit mitochondrial network and escape p53-driven apoptosis," Oncogenesis, vol. 8, no. 3, 2019.

[73] A. R. Demonbreun, K. A. Lapidos, K. Heretis et al., "Myoferlin regulation by NFAT in muscle injury, regeneration and repair," Journal of Cell Science, vol. 123, no. 14, pp. 2413–2422, 2010.

[74] C. Hermans, V. Hampl, K. Holzer et al., "The novel MKL target gene myoferlin modulates expansion and senescence of hepatocellular carcinoma," Oncogene, vol. 36, no. 24, pp. 3464–3476, 2017.

[75] V. Hampl, C. Martin, A. Aigner et al., "Depletion of the transcriptional coactivators megakaryoblastic leukaemia 1 and 2 abolishes hepatocellular carcinoma xenograft growth by inducing oncogene-induced senescence," EMBO Molecular Medicine, vol. 5, no. 9, pp. 1367–1382, 2013.

[76] S. Ohrnberger, A. Thavamani, A. Braeuning et al., "Dysregulated serum response factor triggers formation of hepatocellular carcinoma," Hepatology, vol. 61, no. 3, pp. 979–989, 2015.

[77] C. Leung, C. Yu, M. I. Lin, C. Tognon, and P. Bernatchez, "Expression of Myoferlin in human and murine carcinoma tumors," The American Journal of Pathology, vol. 182, no. 5, pp. 1900–1909, 2013.

[78] W. Zhang, P. Zhou, A. Meng, R. Zhang, and Y. Zhou, "Down-regulating Myoferlin inhibits the vasculogenic mimicry of melanoma via decreasing MMP-2 and inducing mesenchymal-to-epithelial transition," Journal of Cellular and Molecular Medicine, vol. 22, no. 3, pp. 1743–1754, 2018.

[79] A. Yadav, B. Kumar, J. C. Lang, T. N. Teknos, and P. Kumar, "A muscle-specific protein ‘myoferlin’ modulates IL-6/STAT3 signaling by chaperoning activated STAT3 to nucleus," Oncogene, vol. 36, no. 46, pp. 6374–6382, 2017.

[80] K. L. Sachen, M. J. Strohman, J. Singletary et al., "Self-antigen recognition by follicular lymphoma B-cell receptors," Blood, vol. 120, no. 20, pp. 4182–4190, 2012.

[81] H. M. Koh, H. J. An, G. H. Ko et al., "Identification of Myoferlin expression for prediction of subsequent primary malignancy in patients with clear cell renal cell carcinoma," In Vivo, vol. 33, no. 4, pp. 1103–1108, 2019.